Cargando…
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway
Recent studies indicate that constitutive signaling through the phosphatidylinositol 3'-kinase (PI3K) pathway is a cause of treatment resistance in breast cancer patients. This implies that patients with tumors that exhibit aberrant PI3K signaling may benefit from targeted pathway inhibitors. T...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242159/ https://www.ncbi.nlm.nih.gov/pubmed/16168140 http://dx.doi.org/10.1186/bcr1307 |